Apollomics (NASDAQ: APLMW) plans wind-up after U.S. layoffs and trial halt

Rhea-AI Filing Summary

Apollomics Inc. reported that, due to its cash position, it is terminating all U.S. employees, including its Chief Executive Officer, Dr. Guo-Liang Yu, and Chief Financial Officer, Dr. Matthew Plunkett, effective August 29, 2025. This indicates a severe reduction of U.S. operations and leadership.

The company also stated that it expects to discontinue all activities related to its SPARTA clinical trial as soon as possible, signaling a shutdown of this development program. In addition, Apollomics has called an Extraordinary General Meeting of Shareholders for September 4, 2025, to seek shareholder approval for winding up the company, which would effectively bring its corporate existence to an end if approved.

Positive

• None.

Negative

• Termination of all U.S. employees and top executives due to the company’s cash position, including the Chief Executive Officer and Chief Financial Officer, effective August 29, 2025.
• Expected discontinuation of the SPARTA clinical trial, ending a key clinical program as the company moves toward shutting down operations.
• Extraordinary General Meeting called to approve winding up the company on September 4, 2025, indicating a possible full corporate wind-up subject to shareholder approval.

Insights

Biotech restructuring and governance analyst

Apollomics moves toward wind-up, ending U.S. operations and a key trial.

Apollomics Inc. disclosed that, because of its cash position, it is terminating all U.S. employees, including the CEO and CFO, effective August 29, 2025. Cutting all U.S. staff together with top leadership points to an operational shutdown rather than a routine restructuring.

The company also expects to discontinue all activities related to the SPARTA clinical trial as soon as possible, removing a key development effort from its pipeline. In parallel, it has convened an Extraordinary General Meeting on September 4, 2025 to seek shareholder approval to wind up the company, which, if approved, would likely end ongoing business and R&D activities. The disclosure notes this information is incorporated by reference into existing registration statements, aligning securities law disclosures with the company’s potential wind-up.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission file number: 001-41670

Apollomics Inc.

(Exact name of registrant as specified in its charter)

Not Applicable

(Translation of registrant’s name into English)

989 E. Hillsdale Blvd., Suite 220

Foster City, California 94404

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

On August 28, 2025, Apollomics Inc. (the “Company”) announced that due to its cash position, the Company has terminated all U.S. employees, including the Chief Executive Officer, Dr. Guo-Liang Yu, and Chief Financial Officer, Dr. Matthew Plunkett, effective as of August 29, 2025. The Company also announced that it expects to discontinue all activities related to the SPARTA clinical trial as soon as possible.

On August 28, 2025, the Company also announced an Extraordinary General Meeting of Shareholders (the “Meeting”) to be held on September 4, 2025, at 10:00 a.m. PT, to seek shareholder approval of the winding up of the Company. The notice and proxy statement of the Meeting and the form of proxy card are furnished hereto as Exhibits 99.1 and 99.2, respectively.

The information in this Form 6-K relating to the termination of U.S. employees, discontinuation of clinical trial activities and the announcement of the Meeting is incorporated by reference into the Company’s registration statements under the Securities Act, including its registration statements on Form S-8 (File No. 333-272559) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and shall be a part thereof, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits

Exhibit No.		Description
99.1		Notice of the Meeting and Proxy Statement
99.2		Form of Proxy Card

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

				Apollomics Inc.
Date: August 28, 2025				By:		/s/ Guo-Liang Yu
						Guo-Liang Yu, Ph.D. Chief Executive Officer

FAQ

What major actions did Apollomics Inc. (APLMW) disclose in this Form 6-K?

Apollomics Inc. reported that, due to its cash position, it is terminating all U.S. employees, including its Chief Executive Officer and Chief Financial Officer, effective August 29, 2025, expects to discontinue all SPARTA clinical trial activities, and has called an Extraordinary General Meeting to seek shareholder approval for winding up the company.

How are Apollomics Inc.’s executives affected by the announced job terminations?

The company stated that all U.S. employees are being terminated, which includes its Chief Executive Officer, Dr. Guo-Liang Yu, and Chief Financial Officer, Dr. Matthew Plunkett, with their termination effective as of August 29, 2025.

What did Apollomics Inc. say about the SPARTA clinical trial?

Apollomics Inc. announced that it expects to discontinue all activities related to the SPARTA clinical trial as soon as possible, indicating that this clinical program will not continue under the current plan.

Why is Apollomics Inc. holding an Extraordinary General Meeting of Shareholders?

The company has called an Extraordinary General Meeting of Shareholders for September 4, 2025, at 10:00 a.m. PT, to seek shareholder approval of the winding up of the company.

When will Apollomics Inc.’s Extraordinary General Meeting take place and what documents are provided?

The Extraordinary General Meeting is scheduled for September 4, 2025, at 10:00 a.m. PT. The notice and proxy statement for the meeting and the form of proxy card are provided as Exhibits 99.1 and 99.2 to the report.

How does this disclosure interact with Apollomics Inc.’s existing registration statements?

The information about U.S. employee terminations, discontinuation of the SPARTA clinical trial, and the Extraordinary General Meeting is incorporated by reference into the company’s registration statements under the Securities Act, including its Form S-8 and multiple Form F-3 registration statements.